|
Acute Cerebrovascular Accidents
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibiting 12/15-lipoxygenase to treat acute stroke in permanent and tPA induced thrombolysis models.
|
29079502 |
2018 |
|
Acute Undifferentiated Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival.
|
25105362 |
2014 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
A statistically significantly greater number of cases were found to have an elevated level of 12-LOX among T3, high grade, and surgical margin-positive than T2, intermediate, and low grade, and surgical margin-negative prostatic adenocarcinomas.
|
7624992 |
1995 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
LHGDN |
Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging.
|
11023533 |
2000 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
LHGDN |
15-lipoxygenase-1 overexpression in prostate adenocarcinoma.
|
12664577 |
2002 |
|
Adenoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Down-regulation of 15-LOX-1 is an early event in the adenoma to carcinoma sequence, and reversal with celecoxib may represent one mechanism for chemoprevention of polyps or treatment of carcinomas.
|
15912043 |
2005 |
|
Adenoma
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Down-regulation of 15-LOX-1 is an early event in the adenoma to carcinoma sequence, and reversal with celecoxib may represent one mechanism for chemoprevention of polyps or treatment of carcinomas.
|
15912043 |
2005 |
|
Adenoma
|
0.020 |
AlteredExpression
|
group |
LHGDN |
In FAP patients, 15-LOX-1 expression and activity were significantly down-regulated in adenomas (compared with paired nonneoplastic epithelial mucosa), whereas 5-LOX and 15-LOX-2 protein expressions and enzymatic activities were not.
|
16357157 |
2005 |
|
Adenoma of large intestine
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
However, there was an inverse association between the Arg261Gln polymorphism in 12-LOX and colorectal adenoma (OR, 0.63; 95% CI, 0.40-1.00).
|
17236225 |
2007 |
|
Adenoma of large intestine
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
15-LOX-1 gene expression is significantly reduced in both human colorectal adenomas and carcinomas and associated with decreased survival.
|
15912043 |
2005 |
|
Adenomatous Polyposis Coli
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Studies of LOX products in preclinical models and in patients with familial adenomatous polyposis and sporadic colorectal tumorigenesis indicate that LOX pathways are shifted during colonic tumorigenesis and that the main shift is downregulation of 15-LOX-1.
|
22960430 |
2014 |
|
Adrenoleukodystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study investigated the role of bioactive lipid metabolites in alcohol-induced liver damage and tested the potential of targeting arachidonate 15-lipoxygenase (ALOX15) in treating alcoholic liver disease (ALD).
|
28827690 |
2017 |
|
Adult Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study aimed at delineating the transcriptional and epigenetic mechanisms leading to 15-lipoxygenase-1 (15-LOX-1) expression in the Hodgkin lymphoma (HL) cell line L1236.
|
22094113 |
2012 |
|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The 15-LO promoter was exclusively methylated in all examined cells incapable of expressing 15-LO (certain solid tumor and human lymphoma cell lines and human T lymphocytes) while unmethylated in 15-LO-competent cells (the human airway epithelial cell line A549 and human monocytes) where 15-LO expression is IL4-inducible.
|
15194425 |
2004 |
|
Adult Solid Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
The 15-LO promoter was exclusively methylated in all examined cells incapable of expressing 15-LO (certain solid tumor and human lymphoma cell lines and human T lymphocytes) while unmethylated in 15-LO-competent cells (the human airway epithelial cell line A549 and human monocytes) where 15-LO expression is IL4-inducible.
|
15194425 |
2004 |
|
Airway Obstruction
|
0.010 |
Biomarker
|
group |
BEFREE |
Furthermore, co-administration of submaximal doses of the TRPV1 and TRPA1 antagonists or the COX and 12-LOX inhibitors resulted in a greater inhibition of both cough reflex and airway obstruction.
|
31170972 |
2019 |
|
Alcoholic Liver Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
This study investigated the role of bioactive lipid metabolites in alcohol-induced liver damage and tested the potential of targeting arachidonate 15-lipoxygenase (ALOX15) in treating alcoholic liver disease (ALD).
|
28827690 |
2017 |
|
Alopecia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Alox15 KO resulted in loss of hair follicle stem cells and abnormal transition of dermal adipocytes into fibroblasts.
|
29891910 |
2018 |
|
Alzheimer's Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
12/15-Lipoxygenase (12/15-LO) is an enzyme widely distributed in the central nervous system, and it has been involved in the neurobiology of Alzheimer disease (AD).
|
22275252 |
2012 |
|
Alzheimer's Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
The 12/15 lipoxygenase (12/15LOX) enzyme is increased in pathologically affected frontal and temporal regions of Alzheimer's disease (AD) brains compared with controls.
|
16037976 |
2005 |
|
Alzheimer's Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The 12/15-lipoxygenase (12/15-LO) enzyme is upregulated in the brains of patients with Alzheimer's disease (AD), and its expression levels influence the onset of the AD-like phenotype in mouse models.
|
27499089 |
2017 |
|
Alzheimer's Disease
|
0.040 |
Biomarker
|
disease |
LHGDN |
Levels of 12/15-hydroxyeicosatetraenoic acids, metabolic products of 12/15-LOX, were also markedly elevated in AD brains compared to controls.
|
15111312 |
2004 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In vitro experiments performed on amyloid vascular smooth muscle cells showed that a 12-LOX inhibitor almost completely blocked the Aβ<sub>1-40</sub> peptide-induced apoptosis of these cells.
|
29620941 |
2018 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This connection suggests a therapeutic role for ALOX15 inhibitors in amyotrophic lateral sclerosis.
|
24563424 |
2014 |
|
Anoxia
|
0.010 |
AlteredExpression
|
phenotype |
LHGDN |
15-Lipoxygenase-2 expression in human macrophages induces chemokine secretion and T cell migration.
|
18067895 |
2008 |